BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.9M data for 1.2M Compounds and 9.3K Targets. Of those, 1,352K data for 627K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

Advanced Search

18 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
The design and synthesis of novel spirocyclic heterocyclic sulfone ROMK inhibitors as diuretics.EBI
Merck
Differentiation of ROMK potency from hERG potency in the phenacetyl piperazine series through heterocycle incorporation.EBI
Merck Research Laboratories
Discovery of a Potent and Selective ROMK Inhibitor with Pharmacokinetic Properties Suitable for Preclinical Evaluation.EBI
Merck Research Laboratories
Discovery of a novel sub-class of ROMK channel inhibitors typified by 5-(2-(4-(2-(4-(1H-Tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one.EBI
Merck Research Laboratories
Discovery of Selective Small Molecule ROMK Inhibitors as Potential New Mechanism Diuretics.EBI
TBA
Discovery of MK-8153, a Potent and Selective ROMK Inhibitor and Novel Diuretic/Natriuretic.EBI
Merck
Discovery of Small Molecule Renal Outer Medullary Potassium (ROMK) Channel Inhibitors: A Brief History of Medicinal Chemistry Approaches To Develop Novel Diuretic Therapeutics.EBI
University of Nebraska Medical Center
Discovery and in Vitro Optimization of 3-Sulfamoylbenzamides as ROMK Inhibitors.EBI
Pfizer
Improvement of hERG-ROMK index of spirocyclic ROMK inhibitors through scaffold optimization and incorporation of novel pharmacophores.EBI
Merck